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Initiation of newborn screening in the US in 
1999 – endorsed by the Joint Committee on 
Infant Hearing (JCIH)
Early Hearing Detection & Intervention (EHDI) programs:
Advantages: Recordable at birth, Reliable, Quick, Non-invasive, Easily interpreted
Cost effective, Objective, Specifically assesses cochlear function, 
Provides ear specific information, high sensitivity and specificity
UK Newborn Hearing Screening Programmes
• North Wales - NBHSW: started  in March 2003, and in October 2004 
became the first fully implemented national newborn hearing screening 
programme in the UK.
(http://www.wales.nhs.uk/sitesplus/980/home)
• Scotland – UNHSScotland: The roll out across the country was 
completed in December 2005. 15 local programs (~60 000/annum).
(http://www.nsd.scot.nhs.uk)
• NHSP-England: introduced in  a  phased and nationally organized 
process between 2002 and 2006- fully implemented in  March  2006. 113 
local programs covering all births in England (~660 000/annum).
(Wood et al., 2015)
• Ireland -Newborn Hearing Screening Programme: 2011- rolled out in 
19 hospitals
Clinical applications of OAEs
1. Hearing Screening 
a. Newborn hearing screening
b. Pre/school aged children screening
c. Occupational noise exposure screening 
2. Monitoring of cochlear function
a. Ototoxicity monitoring, 
b. NIHL and hearing conservation programmes
3. Diagnostic assessment of cochlear function 
a. Sensory vs. Neural HL (ANSD, APD, AN, Autism)
b. NOHL (non-organic hearing loss)
c. Non-cooperative subjects
4. Assessment of Inhibitory Efferent Olivocochlear Pathway 
Ototoxicity
• Damage to hearing and/or balance function 
following exposure to certain drugs or solvents
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Courtesy of Dr. Ruth Taylor & Prof. Andy Forge (Ear Institute, UCL)
Brummett 1980; Komune et al. 1981; Nakai et al.1982; Konishi et al. 1983; Schweitzer et al. 1984
Genetic susceptibility to Aminoglycoside ototoxicity –
mtDNA A1555G mutation
Bitner-Glindzicz M et al. Arch Dis Child 2010;95:153-155
Rationale for Ototoxicity Monitoring
• Early detection of hearing loss --> Potential Treatment 
modification --> Prevention of further loss
• Enable clinicians to make informed choices:
– Limit the dose of the drug
– Change to an alternative drug
– Alter treatment regimen
– Improve counselling
• Pre- and post treatment counselling offered to the patient
– Provide realistic expectations
– Allow appropriate treatment planning
– Facilitate early introduction of hearing assistance
– Provide important information for post treatment planning 
in order to ensure an acceptable quality of life
Methods of auditory monitoring
• Standard pure-tone audiometry (0.25-8 kHz)
(Riethmueller et al., 2009, Mulherin et al., 1991, Mulheran et al., 2001). 
• High-frequency audiometry (9-20 kHz) 
(Knight et al. 2007)
– Sensitive Range for Ototoxicity (SRO) (Fausti et al., 2005)
• Distortion-product otoacoustic emissions (DPOAEs) 
(Rybak et al., 2009,Lonsbury-Martin and Martin, 2003, Fausti et al., 1992, 
Stavroulaki et al. 2001, 2002, Campbell et al., 2003,)
– Ototoxicity Risk Assessment (ORA) model (Dille et al., 2010)
• Others: Speech Audiometry, ABR, ASSR
How often to repeat the testing?
The ASHA recommended ototoxicity monitoring protocol for oncology patients 
(ASHA, 2013)
Why use 
OAEs in 
monitoring 
ototoxicity?
Pros	 Cons	
Both	TE	and	DP	OAEs	are	highly	
sensitive	to	OHC	cochlear	
dysfunction	
OAEs	can	be	affected/stopped	by	
ME	changes	e.g.	otitis	media		
Most	ototoxic	drugs	affect	the	
OHCs	first	
Changes	in	ME	pressure	can	affect	
repeatability	of	recordings	
OAEs	allow	for	earlier	
identification	of	cochlear	damage	
before	it	is	evident	through	
audiometry	
Repeatability	can	be	affected	by	
probe	fitting,	time	difference	from	
baseline,	and	changes	in	middle	
ear	condition	
DPOAEs	can	detect	basal	cochlear	
HF	damage	before	PTA	speech	
frequencies	(0.5-8kHz)		
OAE	Equipment	may	not	be	
readily	available	in	all	healthcare	
settings	(cost	implications)	
OAEs	are	objective	–	can	be	
performed	in	young	/very	ill	
patients	
Absence	of	agreed	pass/fail	or	
significant	change	criteria	
Test	time	is	brief-	usually	only	
1-2	mins	needed		
	
Only	quiet	testing	environment	
needed		
	
Hand-held	/	Portable	
equipment	-		go	to	patient		
	
High	degree	of	detailed	(8-16	
points/octave)	frequency	
selective	information	can	be	
provided.		
	
	
Use of different tools & criteria 
Author Study method Criteria for 
ototoxicity (HL)
Results Frequency
Pendersen et 
al, 1987
Standard PTA 
(0.25-8kHz)
EHF PTA 
(4-20 kHz)
≥ 15dB 2/42 (5%) Only at high 
freq ≥ 8 kHz
Scheenstra et 
al, 2006
Standard PTA 
(0.25-8kHz)
EHF PTA 
(8-20 kHz)
≥ 20 dB (1 freq) 13/27 
(48.1%)
Only 7/27 
(25.1%) with 
standard PTA
Mulheran et al, 
2001
Standard PTA 
(0.25-8kHz)
EHF PTA 
(10-16 kHz)
≥ 20 dB (≥ 2 Freq) 
or
≥ 25 (1 freq)
17% - mainly 
adults
Conrad et al, 
2008
Standard PTA 
(1-8kHz)
DPOAE (841-
7996Hz)
≥ 25dB or
Abnormal DPOAE
50.8%
Grading Systems/Criteria For Defining Ototoxicity 
ASHA criteria for ototoxicity (1994)
(A) 20 dB or greater increase (worsening) in pure tone threshold at one test frequency
OR
(A) 10 dB or greater increase at two adjacent test frequencies
OR
(C) Loss of response at 3 consecutive test frequencies where baseline responses were previously
obtained, signifying a decrease in hearing following treatment
Brock’s grading criteria for ototoxicity (1991)
Grade Thresholds
0 < 40 dB at 500 - 8,000 Hz
1 ≥ 40 dB at 8,000 Hz
2 ≥ 40 dB at 4,000-8,000 Hz
3 ≥ 40 dB at 2,000-8,000 Hz
4 ≥ 40 dB at 1,000-8,000 Hz
Grading Systems/Criteria For Defining Ototoxicity 
SIOP Boston Ototoxicity Scale (2012)
Grade Parameters
0 ≤ 20 dB HL at all frequencies
1 > 20 dB HL (i.e. 25 dB HL or greater) SNHL above 4,000 
Hz (i.e. 6 or 8 kHz)
2 > 20 dB HL SNHL at 4,000 Hz and above
3 > 20 dB HL SNHL at 2,000 Hz or 3,000 Hz and above
4 > 40 dB HL (i.e. 45 dB HL or more) SNHL at 2,000 Hz 
and above
Responses to: Do you monitor your 
patients’ hearing for signs of ototoxicity?
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Responses to: What audiological testing is 
conducted for ototoxicity monitoring?
Audiology (N=85),  
n (%) 
Oncology (n=51),  
n (%) 
CF clinicians (N=22), 
n (%) 
PTA (250Hz-8kHz) 64 (75.3%) 15 (29.4%) 19 (86.4%) 
EHFA (above 8kHz) 15 (17.7%) 6   (11.8%) 5   (22.7%) 
TEOAEs 21 (24.7%) 2   (3.9%) 3   (13.6%) 
DPOAEs 20 (23.5%) 1   (2.0%) 3   (13.6%) 
Tympanometry  46 (54.1%) 4  (28.2%) 1   (4.5%) 
ART 8   (9.4%) 1   (2.0%) N/A 
ABR; neurological 1   (1.2%) 1   (2.0%) N/A 
ABR; threshold 8   (9.4%) 1   (2.0%) N/A 
Speech audiometry  5   (5.9%) 4   (7.8%) N/A 
I’m not sure which 
audiological tests are 
conducted 
34 (66.7%) 
Comments to: What changes in audiological results 
should prompt change in medical management?
PASS Criteria:
• 2 out of 4 frequency bands (e.g. 1,1.5, 2, 3, 4kHz) reach a signal-to-noise ratio 
(SNR) of at least 6dB
• Total TEOAE of 0dBspl (across all frequencies) 
• OAE in each pass band of at least -5dBspl.
http://www.otodynamics.com/screening8.asp
Pass Criteria for Newborn screening
How to do it – use agreed parameters
DPOAE	Test	parameters	for	a	Diagnostic	monitoring	protocol	
L1/L2	intensity	(dB	SPL)	 65/55*		
F2/F1	ratio	 1.22	
F2	range	(kHz)	 2-10	kHz	
Start	frequency	 2000	Hz	
End	frequency	 10,000	Hz	
Points/octave	 8	(4-16)	
Stopping	criteria	 	
Min	DP	Amplitude	(dB)	 -5																	(as	specified	by	manufacturer/protocol)	
Noise	Floor	(dB)	 -20															(as	specified	by	manufacturer/protocol)	
S/N	Ratio	(dB)	 6																			(as	specified	by	manufacturer/protocol)	
Point	time	limit	(sec)	 20	
L1/L2	intensity	(dB	SPL)	 ±	3dB										(within	Target	levels)	
Sample	size	 1024											(as	specified	by	manufacturer/protocol)	
Number	of	tests	 1	
Minimum	♯Samples	 50																(as	specified	by	manufacturer/protocol)	
	Example of a DPOAE test parameters protocol for ototoxicity monitoring. *(Decrease 
intensity to increase sensitivity)
Prerequisites for recording DPOAEs
• Unobstructed external ear canal 
• Optimal positioning of the OAE probe
• Ability to seal the ear canal with the probe
• Absence of middle ear pathology
• Functioning cochlear OHCs
• Relatively quiet conditions:
• A quiescent patient to avoid internal noises such as 
vocalization, breathing or crying
• A quiet recording environment –yet a sound-proof 
room is not required 
= Avoids artifacts
Change in DPOAEs with repeated testing
http://www.hearingreview.com/2013/10/an-overview-of-oaes-and-normative-data-for-dpoaes/
Pictures courtesy of Otodynamics Ltd.
Example of DPOAE output
DPOAE recording for high frequency (2-10kHz) responses at 8 points/octave. (Picture courtesy of Interacoustics
Ltd.)
Repeatability of DPOAE testing
Mean ±SE DPOAE f2 amplitudes for each of three within session recordings with 
probe refitting – similar findings with Roede et al.,1993; Beattie and Bleech, 2000;
Beattie et al., 2003; Dreisback et al., 2006
What constitutes a significant change?
	
	
Days	
From	
Baseline	
DPOAE	f2	Frequency	
	
1000	Hz	 2000	Hz	 4000	Hz	 6000	Hz	
SEM	 90%	
Reference	
Limits	
SEM	 90%	
Reference	
Limits	
SEM	 90%	
Reference	
Limits	
SEM	 90%	
Reference	
Limits	
1	 1.7	 ±3.95	 1.7	 ±3.98	 1.8	 ±4.16	 1.6	 ±3.76	
10	 1.8	 ±4.24	 1.9	 ±4.35	 2.1	 ±4.85	 2.0	 ±4.55	
15	 1.9	 ±4.41	 2.0	 ±4.56	 2.3	 ±5.24	 2.1	 ±4.99	
20	 2.0	 ±4.57	 2.0	 ±4.76	 2.4	 ±5.63	 2.3	 ±5.43	
	
Reavis et al, 2015: Meta-Analysis of DPOAE Retest Variability for Serial Monitoring of 
Cochlear Function in Adults
Metanalysis of results of 10 studies assessing significant change criteria 
(±6dB change is considered significant with a 10% possible false positive (referral) 
rate). 
Dreisback et al., 2006: (Repeatability of HF 
(>8kHz) DPOAEs)
• The average DPOAE level differences-between-trials for the higher 
and lower frequencies was 5.15 (SD ± 4.40 dB) and 2.80 (SD ± 2.70 
dB) dB, respectively. 
• Individual subject analysis revealed that high-frequency DPOAE levels 
varied no more than 10 dB for 87.5 and 83.1% of young adult subjects 
for the 70/55 and 60/50 dB SPL stimulus level conditions, respectively.
• For low frequencies, repeated DPOAE level variations were within 10 
dB for 98.4 and 96%.
• when monitoring high-frequency DPOAEs if a change of 10 dB or 
more is noted at adjacent frequencies, that trial should be retested to 
determine if the change was due to artifact or a true change in the 
auditory system
Limitations & Cautions when using 
specific change criteria
• Patient population tested may affect variability
• Stimulus frequency/level used for monitoring
• Multiple test frequencies vary in test-retest variability
• Clinician test-retest variability
• Follow-up for significant DPOAE change should be followed 
up by a more detailed test battery 
• Consider Risk Factors/ Predictors of ototoxicity
– Pre-exposure hearing status (prior cochlear damage)
– Radiation treatment
– Concomitant noise / ototoxic drug exposure
– Cumulative exposure to ototoxic drug
How to record/report results
Monitor/audit your service
• Your service is as strong as it’s weakest link – you 
need to ensure that all members of the team are 
keen, involved, aware of their roles and 
responsibilities towards the monitoring program.
• Annual auditing of the service is needed until all 
restrictions/ obstacles are dealt with 
Audiologists as leaders - AAA, 2009
• Audiology professionals should take the lead in:
– Clinical guidelines for minimum standards of monitoring & care 
– Setting up this service and establishing good links and alliances 
with:
• Physicians (oncology, CF,TB, ICU, Renal)
• Specialist Nurses, and Nurses
• Pharmacists
– Professional education programmes to increase awareness and 
standardisation of monitoring practice.
Take Home Messages:
• DPOAEs can be a very useful and effective 
ototoxicity monitoring tool especially in unwell 
bedridden patients
• Repeatability and accuracy of testing can be 
established by consistent deep good probe fitting 
and testing in a quiet environment with established 
normative data.
• Urgent need for establishing an agreed National 
Ototoxicity Monitoring Protocol with set testing 
and outcomes parameters to confirm early evidence 
of ototoxicity & provide consistent minimum level of 
care.  
WHO Recommended roadmap for the 
prevention of hearing loss
Member States of the World Health Organization are required to:
• prepare national plans for the prevention and control of major causes 
of avoidable hearing loss and for early detection of such loss;
• take advantage of existing guidelines and regulations or introduce 
appropriate legislation for the proper management of particularly 
important causes of deafness and hearing impairment, such as otitis 
media, use of ototoxic drugs and harmful exposure to noise, including 
noise in the work environment and loud music;
• ensure appropriate public information and education for hearing 
protection and conservation in particularly vulnerable or exposed 
population groups.
Resolution WHA48.9. Prevention of hearing impairment. In: Forty-eighth World Health Assembly, Geneva, 12 May 1995. Twelfth plenary 
meeting, Committee A Geneva: World Health Organization; 1995. Available from: http://www.who.int/pbd/publications/wha_eb/wha48_9/en/
Go Global !
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